Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Single-Arm Study of Bempegaldesleukin (NKTR-214) in Combination With Nivolumab in Cisplatin Ineligible, Locally Advanced or Metastatic Urothelial Cancer Patients

NCT03785925 is registered in ClinicalTrials.gov with Nektar Therapeutics as lead sponsor.

NCT NCT03785925
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03785925 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Single-Arm Study of Bempegaldesleukin (NKTR-214) in Combination With Nivolumab in Cisplatin Ineligible, Locally Advanced or Metastatic Urothelial Cancer Patients
Lead sponsor
Nektar Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
April 29, 2019
Completion date
June 30, 2022
Enrollment
192 (actual)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasm metastasis, urinary bladder neoplasm